Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.7 EUR
16.61 M EUR
115.50 M EUR
3.12 M
About PHARMANUTRA
Sector
Industry
CEO
Andrea Lacorte
Website
Headquarters
Pisa
Founded
2003
ISIN
IT0005274094
FIGI
BBG00YQ79323
Pharmanutra SpA develops nutraceutical products and medical devices. Its Sroscaloidal Iron intends to restore articular and movement ability in osteoarticular affections, consisting of cetilar line. The company was founded by Andrea Lacorte and Roberto Lacorte in 2003 and is headquartered in Pisa, Italy.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 761 is 50.8 EUR — it has decreased by −0.78% in the past 24 hours. Watch PHARMANUTRA S.P.A. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange PHARMANUTRA S.P.A. stocks are traded under the ticker 761.
761 stock has risen by 4.63% compared to the previous week, the month change is a 3.67% rise, over the last year PHARMANUTRA S.P.A. has showed a −5.05% decrease.
We've gathered analysts' opinions on PHARMANUTRA S.P.A. future price: according to them, 761 price has a max estimate of 88.00 EUR and a min estimate of 74.00 EUR. Watch 761 chart and read a more detailed PHARMANUTRA S.P.A. stock forecast: see what analysts think of PHARMANUTRA S.P.A. and suggest that you do with its stocks.
761 stock is 1.39% volatile and has beta coefficient of 0.34. Track PHARMANUTRA S.P.A. stock price on the chart and check out the list of the most volatile stocks — is PHARMANUTRA S.P.A. there?
Today PHARMANUTRA S.P.A. has the market capitalization of 489.77 M, it has increased by 7.29% over the last week.
Yes, you can track PHARMANUTRA S.P.A. financials in yearly and quarterly reports right on TradingView.
PHARMANUTRA S.P.A. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
761 net income for the last quarter is 3.44 M EUR, while the quarter before that showed 4.27 M EUR of net income which accounts for −19.52% change. Track more PHARMANUTRA S.P.A. financial stats to get the full picture.
Yes, 761 dividends are paid annually. The last dividend per share was 0.85 EUR. As of today, Dividend Yield (TTM)% is 1.67%. Tracking PHARMANUTRA S.P.A. dividends might help you take more informed decisions.
PHARMANUTRA S.P.A. dividend yield was 1.84% in 2024, and payout ratio reached 57.85%. The year before the numbers were 1.51% and 64.04% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 18, 2025, the company has 118 employees. See our rating of the largest employees — is PHARMANUTRA S.P.A. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMANUTRA S.P.A. EBITDA is 30.23 M EUR, and current EBITDA margin is 26.11%. See more stats in PHARMANUTRA S.P.A. financial statements.
Like other stocks, 761 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMANUTRA S.P.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMANUTRA S.P.A. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMANUTRA S.P.A. stock shows the sell signal. See more of PHARMANUTRA S.P.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.